Opthea Ltd
ASX:OPT

Watchlist Manager
Opthea Ltd Logo
Opthea Ltd
ASX:OPT
Watchlist
Price: 0.6 AUD Market Closed
Market Cap: 820.8m AUD

Net Margin
Opthea Ltd

-651 164%
Current
-230 607.7%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-651 164%
=
Net Income
-162.8m
/
Revenue
25k

Net Margin Across Competitors

Country Company Market Cap Net
Margin
AU
Opthea Ltd
ASX:OPT
820.8m AUD
-651 164%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
395B USD
4%
US
Amgen Inc
NASDAQ:AMGN
176.5B USD
19%
US
Gilead Sciences Inc
NASDAQ:GILD
151.9B USD
28%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.3B USD
31%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.6B USD
32%
AU
CSL Ltd
ASX:CSL
84.8B AUD
19%
NL
argenx SE
XBRU:ARGX
44.4B EUR
43%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.8B USD
1%
No Stocks Found

Opthea Ltd
Glance View

Market Cap
820.8m AUD
Industry
Biotechnology

Opthea Ltd. is a clinical stage biopharmaceutical company that engages in the development of biological therapeutics for the treatment of progressive retinal diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in developing and commercializing therapies primarily for eye diseases. The firm's lead product candidate OPT-302, is a soluble form of vascular endothelial growth factors-3 (VEGFR 3) in clinical development as a therapy for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The firm's technology platform focuses on vascular endothelial growth factors, such as VEGF C, VEGF D and VEGF Receptor 3 for the treatment of diseases associated with blood and lymphatic vessel growth (angiogenesis and lymphangiogenesis), as well as vascular leakage. The company has also conducted various activities to support its clinical development programs in wet AMD and DME, including clinical data analysis and manufacturing of OPT-302 for use in Phase III clinical trials.

OPT Intrinsic Value
HIDDEN
Show
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-651 164%
=
Net Income
-162.8m
/
Revenue
25k
What is the Net Margin of Opthea Ltd?

Based on Opthea Ltd's most recent financial statements, the company has Net Margin of -651 164%.

Back to Top